Pricing & Access· July 1, 2026 · 17 min read
CDK4/6 Inhibitor Access Landscape: Payer Dynamics After Ibrance's Expansion
By Ran Chen#Oncology#Breast Cancer#Payer Coverage
Topic
Prior Authorization
Documentation, step edits, renewal cycles, appeals, and how payer criteria shape real-world drug use.
Pricing & Access· June 28, 2026 · 21 min read
Casgevy Access Guide: CMS CGT Model, State Medicaid Criteria, and the ATC Network
By Ran Chen#Medicaid#Prior Authorization#Gene Therapy
Manufacturing· June 15, 2026 · 11 min read
ADHD stimulant shortage: 222 records, 75 not fully available, 3-year median age
Evidence· June 15, 2026 · 11 min read
DOACs in FAERS: 330,426 adverse-event reports by the numbers
By Ran Chen#DOAC#Real-World Evidence#Label Warnings
Policy· June 14, 2026 · 12 min read
How to read an FDA drug label on DailyMed: indication scope, boxed warnings, and PA
Pricing & Access· June 10, 2026 · 10 min read
Bispecific antibody access landscape for myeloma and lymphoma
Pricing & Access· June 10, 2026 · 9 min read
CAR-T cell therapy access landscape: seven products in 2026
By Ran Chen#CAR-T#Oncology#Prior Authorization
Pricing & Access· June 10, 2026 · 10 min read
PD-1/PD-L1 checkpoint inhibitor access landscape in 2026
Pricing & Access· June 9, 2026 · 10 min read
Awiqli coverage guide: insulin icodec access, PA criteria, and Part D pricing
Pipeline· June 7, 2026 · 9 min read
Cytisinicline smoking cessation PDUFA preview: first new pharmacotherapy in 20 years
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence